These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 24080309)

  • 21. Interferon-beta up-regulates the expression of co-stimulatory molecules CD80, CD86 and CD40 on monocytes: significance for treatment of multiple sclerosis.
    Marckmann S; Wiesemann E; Hilse R; Trebst C; Stangel M; Windhagen A
    Clin Exp Immunol; 2004 Dec; 138(3):499-506. PubMed ID: 15544628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of IFN-beta therapy on the frequency and function of CD4(+)CD25(+) regulatory T cells and Foxp3 gene expression in relapsing-remitting multiple sclerosis (RRMS): a preliminary study.
    Namdar A; Nikbin B; Ghabaee M; Bayati A; Izad M
    J Neuroimmunol; 2010 Jan; 218(1-2):120-4. PubMed ID: 19932513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expansion of CD4+CD28- T cells producing high levels of interferon-{gamma} in peripheral blood of patients with multiple sclerosis.
    Miyazaki Y; Iwabuchi K; Kikuchi S; Fukazawa T; Niino M; Hirotani M; Sasaki H; Onoé K
    Mult Scler; 2008 Sep; 14(8):1044-55. PubMed ID: 18573819
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients.
    Raϊch-Regué D; Grau-López L; Naranjo-Gómez M; Ramo-Tello C; Pujol-Borrell R; Martínez-Cáceres E; Borràs FE
    Eur J Immunol; 2012 Mar; 42(3):771-82. PubMed ID: 22488365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo effects of recombinant-interferon-beta1b treatment on polymorphonuclear cell and monocyte functions and on T-cell-mediated antibacterial activity in patients with relapsing-remitting multiple sclerosis.
    Maffione AB; Tatò E; Losito S; Nacci C; Mitolo V; Troiano M; Ruggieri M; Livrea P; Jirillo E
    Immunopharmacol Immunotoxicol; 2000 Feb; 22(1):1-18. PubMed ID: 10737253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multiple sclerosis-associated retroviral agent (MSRV)-stimulated cytokine production in patients with relapsing-remitting multiple sclerosis.
    Saresella M; Rolland A; Marventano I; Cavarretta R; Caputo D; Marche P; Perron H; Clerici M
    Mult Scler; 2009 Apr; 15(4):443-7. PubMed ID: 19251836
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Simvastatin inhibits secretion of Th17-polarizing cytokines and antigen presentation by DCs in patients with relapsing remitting multiple sclerosis.
    Zhang X; Tao Y; Wang J; Garcia-Mata R; Markovic-Plese S
    Eur J Immunol; 2013 Jan; 43(1):281-9. PubMed ID: 23076801
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta.
    Durelli L; Conti L; Clerico M; Boselli D; Contessa G; Ripellino P; Ferrero B; Eid P; Novelli F
    Ann Neurol; 2009 May; 65(5):499-509. PubMed ID: 19475668
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interferon beta-induced restoration of regulatory T-cell function in multiple sclerosis is prompted by an increase in newly generated naive regulatory T cells.
    Korporal M; Haas J; Balint B; Fritzsching B; Schwarz A; Moeller S; Fritz B; Suri-Payer E; Wildemann B
    Arch Neurol; 2008 Nov; 65(11):1434-9. PubMed ID: 19001161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Compromised CD4+ CD25(high) regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level.
    Venken K; Hellings N; Thewissen M; Somers V; Hensen K; Rummens JL; Medaer R; Hupperts R; Stinissen P
    Immunology; 2008 Jan; 123(1):79-89. PubMed ID: 17897326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of Fas antigen on T cell subpopulations in peripheral blood of patients with relapsing-remitting multiple sclerosis.
    Bilińska M; Frydecka I; Podemski R; Teodorowska R; Gruszka E
    Med Sci Monit; 2001; 7(2):251-5. PubMed ID: 11257731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of sex hormones on costimulatory molecule expression in multiple sclerosis.
    Pelfrey CM; Moldovan IR; Cotleur AC; Zamor N; Rudick RA
    J Neuroimmunol; 2005 Oct; 167(1-2):190-203. PubMed ID: 16046001
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential screening-selected gene aberrative in neuroblastoma (DAN) is increased in the CSF of patients with MS and may be induced by therapy with interferon-β.
    Mausner-Fainberg K; Kolb H; Penn M; Regev K; Vaknin-Dembinsky A; Gadoth A; Kestenbaum M; Karni A
    J Neuroimmunol; 2016 Mar; 292():93-6. PubMed ID: 26943965
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment.
    Krumbholz M; Theil D; Cepok S; Hemmer B; Kivisäkk P; Ransohoff RM; Hofbauer M; Farina C; Derfuss T; Hartle C; Newcombe J; Hohlfeld R; Meinl E
    Brain; 2006 Jan; 129(Pt 1):200-11. PubMed ID: 16280350
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IFN-beta-regulated genes show abnormal expression in therapy-naïve relapsing-remitting MS mononuclear cells: gene expression analysis employing all reported protein-protein interactions.
    Yamaguchi KD; Ruderman DL; Croze E; Wagner TC; Velichko S; Reder AT; Salamon H
    J Neuroimmunol; 2008 Mar; 195(1-2):116-20. PubMed ID: 18279974
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression.
    Krakauer M; Sorensen P; Khademi M; Olsson T; Sellebjerg F
    Mult Scler; 2008 Jun; 14(5):622-30. PubMed ID: 18424480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunoregulatory T cells in multiple sclerosis and the effect of interferon beta and glatiramer acetate treatment on T cell subpopulations.
    Praksova P; Stourac P; Bednarik J; Vlckova E; Mikulkova Z; Michalek J
    J Neurol Sci; 2012 Aug; 319(1-2):18-23. PubMed ID: 22676847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The B1-cell subpopulation is diminished in patients with relapsing-remitting multiple sclerosis.
    Tørring C; Petersen CC; Bjerg L; Kofod-Olsen E; Petersen T; Höllsberg P
    J Neuroimmunol; 2013 Sep; 262(1-2):92-9. PubMed ID: 23856341
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis.
    Weber F; Polak T; Günther A; Kubuschok B; Janovskaja J; Bitsch A; Poser S; Rieckmann P
    Ann Neurol; 1998 Jul; 44(1):27-34. PubMed ID: 9667590
    [TBL] [Abstract][Full Text] [Related]  

  • 40. B cells as a therapeutic target for IFN-β in relapsing-remitting multiple sclerosis.
    Ramgolam VS; Sha Y; Marcus KL; Choudhary N; Troiani L; Chopra M; Markovic-Plese S
    J Immunol; 2011 Apr; 186(7):4518-26. PubMed ID: 21368231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.